Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
809 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.
Mostaghimi A, Gooderham MJ, Lynde C, Sinclair R, King B, Hordinsky M, Rudnicka L, Guttman-Yassky E, Serrao R, Ohyama M, Zhang X, Magnolo N, Kwon O, Oddi C, Meerwein S, Soliman AM, Bu X, Duan C, Wu T, Teixeira HD, Lazar A, Passeron T. · JAMA Dermatol · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- Skin cancer risk in alopecia areata: a systematic review and meta-analysis.
Gaumond SI, Abdshah A, Kamholtz I, Warp PV, Nouri K, Tosti A, Jimenez JJ. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Acupuncture for treating alopecia areata: A systematic review and meta-analysis.
Jun JH, Lee HW, Choi TY, Lee MS. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials.
Xia Y, Chen H, Chen Y, Chen Z. · Postgrad Med J · 2026 · cited 0 timescomparative study, network meta-analysis
- Epidemiology and burden of alopecia areata in Taiwan: a systematic review.
Yang CC, Ma SH, Yen PJ, Lin HW, Chen KA, Chen CC. · Front Med (Lausanne) · 2025 · cited 1 timesOpen accesssystematic review, systematic-review
- Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.
Senna M, Hanna S, Ueki R, Zhang X, Aguh C, Piraccini BM, Wajsbrot D, Nagy E, Sadrarhami M, Chen S, Wolk R, Tran H, Lejeune A. · Am J Clin Dermatol · 2026 · cited 2 timesOpen accessclinical trial, phase iii, clinical trial, phase ii
- Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Morriss S, Foo CH, Lin E, Rodrigues Dias F, Kushnir-Grinbaum D, FitzGerald H, Leemaqz S, Lee S, Bhoyrul B. · Am J Clin Dermatol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study.
Facheris P, Gargiulo L, Ibba L, Valenti M, D'Oria F, Foggi G, Falcidia C, Di Giulio S, Vignoli CA, Costanzo A, Narcisi A. · Dermatol Ther (Heidelb) · 2026 · cited 1 timesOpen accesssystematic review, review-article
- Measurement Instruments to Assess Quality of Life in Pediatric Patients With Alopecia Areata: A Systematic Review.
Mehta S, Metko D, McMullen E, Sibbald C. · Pediatr Dermatol · 2026 · cited 0 timesOpen accessbrief-report, systematic review
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.
Ueki R, Mizuashi M, Harada K, Zhang X, Wu W, Chung WH, Kwon O, Luo X, Basey V, Wolk R, Shi N, Fujita K, Shen Y, Hirose T. · J Dermatol · 2026 · cited 0 timesOpen accessclinical trial, phase iii, clinical trial, phase ii
- Exosome-Based Therapies for Alopecia Areata: A Systematic Review of Clinical and Experimental Evidence.
Bulgaru-Iliescu AI, Moraru DC, Amarandei AH, Avadanei-Luca S, Constantinescu MC, Rusu AC, Pertea M. · Int J Mol Sci · 2025 · cited 2 timesOpen accesssystematic review, review-article
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial.
King B, Ehst B, Foley P, Reygagne P, Ohyama M, Szepietowski JC, Popmihajlov Z, De Leonardis F, Hippeli L, Treitel M, Johnson B, Gilvary C, Vaile J, Daamen C, Passeron T. · Br J Dermatol · 2026 · cited 3 timesclinical trial, phase ii, multicenter study
- A meta-analysis of chemokines in alopecia areata: recruiting immune cells toward the hair follicle.
Van Caelenberg E, Belpaire A, van Geel N, Speeckaert R. · Front Immunol · 2025 · cited 1 timesOpen accessmeta-analysis, scoping review
- Association between alopecia areata and cardiovascular disease: a systematic review and meta-analysis.
Lu J, Cao X, Feng Y, Yu Y, Lu Y. · Front Immunol · 2025 · cited 0 timesOpen accessmeta-analysis, systematic review
- Immune-Mediated Disorders in Patients With Alopecia Areata: Systematic Review and Meta-Analysis.
Krajewski PK, Jastrząb B, Szepietowski JC, Jankowska-Konsur A, Saceda Corralo D. · Int J Dermatol · 2025 · cited 4 timesmeta-analysis, systematic review
- Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial.
Zhou C, Yang C, Fan W, Wu J, Yang D, Jin H, Yang Q, Hu G, Lin N, Yang X, Wan J, Zhang J, Wu L, Dai Y, Ma L, Li S, Su J, Sun J, Ding Y, Xiao R, Zhang S, Jiang W, Wang L, Zhang J. · J Am Acad Dermatol · 2026 · cited 4 timesclinical trial, phase iii, research support, non-u.s. gov't
- Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial.
Blume-Peytavi U, Piraccini BM, Reygagne P, Guiraud J, Mukherjee B, Guichard A, Liu J, Pralong W, Harti S. · Br J Dermatol · 2026 · cited 1 timesclinical trial, phase iii, clinical trial, phase ii
- Tolerability and efficacy of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients with moderate to severe alopecia areata.
Wan M, Zhang M, Song X, Yu N, Deng S, Zhou C, Hu T, Song Z, Yang X. · J Am Acad Dermatol · 2026 · cited 1 timescomparative study, multicenter study
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy.
Xi L, Peeva E, Yamaguchi Y, Ye Z, Lejeune A, Hyde C, Guttman-Yassky E. · Allergy · 2025 · cited 4 timesOpen accessclinical trial, phase ii
- Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib.
Mostaghimi A, Craiglow B, King B, Shapiro J, Ko J, Tosti A, Ohyama M, Brogan Y, Yu G, Sontag A, Somani N. · Br J Dermatol · 2025 · cited 6 timesmulticenter study, randomized controlled trial
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study.
Gupta AK, Bamimore MA, Mirmirani P, Piguet V, Talukder M. · J Cosmet Dermatol · 2025 · cited 9 timesOpen accesssystematic review, network meta-analysis
- Familial patterns of alopecia areata: A systematic review and meta-analysis.
Huang Y, Jee E, Kim M, Liu X, Jiang X. · J Autoimmun · 2025 · cited 3 timesmeta-analysis, systematic review
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making.
Mauer J, Whichello C, Hauber B, Krucien N, Law EH, Trapali M, Senna M, Zwillich SH, Wolk R, Tervonen T. · Value Health · 2026 · cited 0 timesclinical trial, phase iii, clinical trial, phase ii
- Integrated Meta-Analysis of Scalp Transcriptomics and Serum Proteomics Defines Alopecia Areata Subtypes and Core Disease Pathways.
Xi L, Peeva E, Yamaguchi Y, Ye Z, Hyde CL, Guttman-Yassky E. · Int J Mol Sci · 2025 · cited 6 timesOpen accessmeta-analysis
- Alopecia Areata-Specific Patient-Reported Outcome Measures: A Systematic Review.
Darchini-Maragheh E, Moussa A, Yoong N, Bokhari L, Jones L, Sinclair R. · JAMA Dermatol · 2025 · cited 3 timessystematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.